Precision oncology startup Black Diamond Therapeutics announced an underwritten public offering of 15 million common shares. The company aims to raise approximately USD 75 million at a price of USD 5.00 per share.
The offering will be managed by Piper Sandler as a sole book-running manager and Wedbush PacGrow as the lead manager.
Additionally, the company has granted underwriters a 30-day option to purchase an additional 2.25 million shares at the same price. The offering is expected to close on July 5, 2023. The use of net proceeds was not disclosed.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.